Different real-world cohorts exist with divergent results regarding the impact of diabetes on safety and efficacy of TEER: Kaneko et al. (2017) reported that patients with secondary MR and diabetes were more often NT-proBNP nonresponders and therefore concluded that patients with diabetes were nonresponders to TEER using the MitraClip device. The gene discussed is NPPB; the disease is diabetes mellitus.